Table 2.
Clinical characteristics by tertiles of plasma NAMPT and glycemic status in Brazilian cohort
| |
Subjects without type 2 diabetes |
p |
Type 2 diabetes subjects |
p |
||||
|---|---|---|---|---|---|---|---|---|
| T1 | T2 | T3 | T1 | T2 | T3 | |||
| N |
98 |
106 |
97 |
|
100 |
92 |
101 |
|
| Plasma NAMPT(ng/ml) |
3.06 ± 0.74 |
5.02 ± 0.56a |
8.87 ± 2.92ab |
<0.0001 |
3.10 ± 0.73 |
5.00 ± 0.50a |
8.67 ± 2.90ab |
<0.0001 |
| (0.57 – 4.13) |
(4.14 – 6.05) |
(6.08 – 19.92) |
(0.93 – 4.13) |
(4.14 – 6.03) |
(6.08 – 20.18) |
|||
| Age (y) |
57 ± 10 |
59 ± 11 |
59 ± 11 |
0.31 |
59 ± 9 |
61 ± 10 |
64 ± 10a |
0.01 |
| Sex (male) |
58 |
58 |
67 |
0.32 |
46 |
61 |
51 |
0.11 |
| BMI (kg/m2) |
26.8 ± 4.3 |
25.6 ± 4.2 |
25.3 ± 4.4a |
0.04c |
28.5 ± 5.3 |
27.5 ± 4.6 |
28.2 ± 4.5 |
0.31c |
| Waist circumference (cm) |
97 ± 12 |
90 ± 14 |
92 ± 12 |
0.05c |
102 ± 12 |
98 ± 12 |
99 ± 12 |
0.19c |
| Fasting Plasma Glucose (mmol/l) |
5.6 ± 0.6 |
5.5 ± 0.6 |
5.4 ± 0.5 |
0.07 |
8.6 ± 3.7 |
8.1 ± 3.0 |
7.9 ± 2.6 |
0.38 |
| HbA1c (%) |
5.8 ± 0.4 |
5.9 ± 0.4 |
5.7 ± 0.4ab |
0.004 |
7.7 ± 1.7 |
7.6 ± 1.6 |
7.8 ± 1.8 |
0.78 |
| LDL cholesterol (mmol/l) |
2.77 ± 0.89 |
2.86 ± 0.93 |
2.59 ± 0.95 |
0.05 |
2.40 ± 0.79 |
2.58 ± 1.01 |
2.55 ± 0.92 |
0.62 |
| HDL cholesterol (mmol/l) |
0.98 ± 0.25 |
1.04 ± 0.28 |
1.01 ± 0.28 |
0.45 |
1.04 ± 0.28 |
0.98 ± 0.29 |
1.00 ± 0.30 |
0.29 |
| Triglycerides (mmol/l) |
1.85 ± 1.53 |
1.54 ± 0.69 |
1.38 ± 0.68a |
0.002 |
1.96 ± 1.22 |
1.94 ± 1.09 |
1.67 ± 0.94a |
0.05 |
| Total adiponectin (μg/ml) |
8.8 ± 6.1 |
10.4 ± 6.9 |
11.2 ± 7.8a |
0.006c |
8.4 ± 5.5 |
8.3 ± 8.1 |
8.5 ± 6.2 |
0.82c |
| Arterial hypertension (%) |
87 |
81 |
87 |
0.44 |
96 |
100 |
95 |
0.15 |
| eGFR (ml/min) |
87 ± 21 |
87 ± 25 |
86 ± 22 |
0.89 |
84 ± 24 |
82 ± 29 |
84 ± 28 |
0.56 |
| Prevalence of CAD (%) |
77 |
64 |
70 |
0.15 |
57 |
67 |
75 |
0.02 |
| Antihypertensive medication (%) |
|
|
|
|
|
|
|
|
| ACEi |
50 |
44 |
42 |
0.52 |
61 |
71 |
65 |
0.31 |
| ARB |
12 |
14 |
13 |
0.92 |
17 |
10 |
10 |
0.23 |
| BB |
41 |
48 |
40 |
0.47 |
57 |
52 |
54 |
0.48 |
| Antidiabetic medication (%) |
|
|||||||
| MTF |
-- |
-- |
-- |
-- |
46 |
45 |
41 |
0.79 |
| SU |
-- |
-- |
-- |
-- |
27 |
22 |
23 |
0.75 |
| INS | -- | -- | -- | -- | 22 | 20 | 33 | 0.10 |
Data expressed as mean ± SD (and range, for plasma NAMPT levels). Statistics for quantitative parameters are ANOVA or ANCOVA with log-transformed data. Tukey Kramer HSD test following ANOVA/ANCOVA: significantly different (p < 0.05) from T1 (a) or T2 (b). Comparison adjusted for age and sex (c). eGFR estimated glomerular filtration rate, UAE urinary albumin excretion rate, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BB beta-blocker MTF metformin, SU sulfonylurea, INS insulin.